



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
July 30, 2026

**Notice Regarding the Capital and Business Alliances
Between Alfresa Corporation and Ember LifeSciences, Inc.
Aimed at Improving Pharmaceutical Cold Chain Transportation Quality
~Provision of pharmaceutical transportation solutions integrating temperature
management, transportation status visualization, and traceability functions~**

Subsidiary Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”), a company engaged in the Ethical Pharmaceuticals Wholesaling Business, has concluded a capital and business alliance agreement with Ember LifeSciences, Inc. The company offers pharmaceutical transportation solutions such as its Ember Cube solution. This solution features temperature management functions for maintaining temperatures between 2°C and 8°C and traceability functions for visualizing location and temperature data in real time via Internet of Things (IoT) technologies. The details of said alliances are as follows.

1. Background and Purpose of the Alliances

In recent years, there has been an increase in specialty and other pharmaceuticals requiring rigorous temperature management. Furthermore, calls for in-home care approaches designed to reduce the burden of patients that would otherwise need to make frequent trips to healthcare institutions have become more frequent, while demand for the delivery of pharmaceutical products to directly to patients' homes is on the rise. These trends are increasing the importance of quality during storage and across all other stages of cold chain pharmaceutical transportation, including last-mile pharmaceutical distribution.

The Alfresa Group, which leads Japan's ethical pharmaceuticals wholesaling industry in terms of net sales,^{*1} has positioned total supply chain services^{*2} as a central pillar of 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength.^{*3} In its total supply chain services, the

Group organically merges its various functions in a unified manner to handle everything from the introduction, development, and manufacture of pharmaceuticals and related products, through to the logistics and sale thereof, to post-marketing surveillance^{*4} and last-mile operations.

Based in the United States, Ember LifeSciences provides the Ember Cube temperature-controlled shipping box, cloud-based monitoring systems, and other solutions for pharmaceutical transportation—which requires rigorous temperature management—to pharmaceutical companies, pharmaceutical wholesalers, and healthcare institutions. By offering such solutions for maintaining temperatures between 2°C and 8°C and by visualizing location and temperature data in real time via IoT technologies, the company is contributing to storage and transportation quality assurance as well as traceability in cold chain pharmaceutical transportation.

Through this alliance, Ember LifeSciences and Alfresa will seek to improve quality throughout all stages of cold chain pharmaceutical transportation in Japan via the provision of the Ember Cube temperature-controlled shipping box, cloud-based monitoring systems, and other solutions. Meanwhile, Alfresa is currently offering Home Care Delivery,^{*5} a safe, secure, and effective service dedicated to delivering necessary specialty pharmaceuticals from healthcare institutions directly to patients' homes. Both parties are examining the possibility of utilizing Ember LifeSciences' solutions in conjunction with Home Care Delivery. Through these efforts, the companies aim to provide safe, secure, and high-quality functions for all stages of cold chain pharmaceutical transportation.

*1 Drug Magazine, "Pharmaceutical Industry Rankings, Top 5 Major Wholesale Groups" section (August 2025 issue, published by Drugmagazine Co., Ltd.)

*2 Such services involve the organic, integrated utilization of the various functions possessed by the Alfresa Group to enable the establishment of a seamless supply chain and the Group's unified provision of services in areas extending from the introduction, development, and manufacture of pharmaceuticals and other products through to their distribution, sale, post-marketing surveillance, and last mile operations.

*3 Notice Regarding the Formulation of the 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength (published on May 15, 2025 on the Alfresa Holdings Corporation corporate website)
https://ssl4.eir-parts.net/doc/2784/ir_material17/250645/00.pdf

*4 Surveillance for ensuring the quality, efficacy, and safety of pharmaceuticals and medical devices after they are put on the market

*5 Commencement of Full-Scale Operation of Home Care Delivery, a Specialized Service for Delivering Specialty Pharmaceuticals to Patients' Homes (published on October 3, 2023 on the Alfresa Holdings Corporation corporate website)
https://ssl4.eir-parts.net/doc/2784/ir_material17/215624/00.pdf

2. Outline of the Capital and Business Alliances

Through investment in Ember LifeSciences, Alfresa will provide funding support to advance the former's technology and business development efforts. At the same time, Alfresa will acquire exclusive rights for the sale of Ember Cube and other Ember LifeSciences solutions in the Japanese healthcare market. Alfresa will also utilize its nationwide pharmaceutical distribution network to conduct sales activities, customer management, and relationship building with logistics companies for the purpose of facilitating the supply of Ember LifeSciences solutions in the domestic healthcare market.

Meanwhile, Ember LifeSciences will provide Alfresa with a reliable supply of Ember Cubes while also offering support with regard to the provision, maintenance, and updating of related systems as well as to technologies and marketing.

3. Characteristics of Ember Cube and other solutions

(1) Two Products Capable of Maintaining Temperatures Between 2°C and 8°C for Over 72 hours

Ember LifeSciences supplies Ember Cube, which controls temperatures with cooling functions powered by batteries or other power supplies, as well as the lighter-weight Ember Cube 2, which controls temperatures using conventional coolants. Both of these products are capable of maintaining temperatures between 2°C and 8°C for over 72 hours.

(2) Real-Time Transportation Monitoring and Traceability

Utilizing IoT technologies, Ember Cube streams location and temperature data from cloud servers to allow for real-time monitoring and enable integrated management of GPS data, temperature, and lid-opening alerts. These features allow users to manage quality and ensure traceability during storage and transportation. Moreover, the dashboard feature provides an intuitive visual representation of location, temperature, and other information during transportation and at other stages.

(3) Designed for Collection and Reuse

Ember Cube is designed for collection and reuse with no disposable packaging. This product is contributing to reductions in total costs as well as in waste and consequently environmental impacts. Moreover, this product automatically generates and displays digital shipping labels, thereby streamlining processes and reducing waste from printed labels.


(4) Highly Rated Design

Ember Cube 2 features a superior design that was recognized as the Best of the Best in the Red Dot Awards: Product Design, a program that sets the global standard for design quality and innovation.

Superior design of Ember Cube 2



Intuitive visual dashboard



4. Overview of Ember LifeSciences, Inc. (as of December 31, 2025)

(1)	Corporate name	Ember LifeSciences, Inc.	
(2)	Head office	Westlake Village, California, United States	
(3)	Name and title of representative	Clay Alexander, Founder & CEO	
(4)	Description of business	Development and supply of pharmaceutical cold chain transportation technologies and solutions including Ember Cube shipping box with self-cooling and cloud connectivity functions for transportation of pharmaceuticals and vaccines requiring temperature management	
(5)	Date of founding	May 20, 2022	
(6)	Relationship between Alfresa Holdings Corporation, Alfresa Corporation, and Ember LifeSciences, Inc.	Capital relationship	None
		Human relationship	None
		Transactional relationship	None
		Related parties	None

5. Timeline

Conclusion of business alliance: June 25, 2026

Conclusion of capital alliance: July 1, 2026

6. Outlook

Although the impact of the agreement on its business performance for the fiscal year ending March 31, 2027 is expected to be minor, the Alfresa Group believes that said agreement will help enhance the Group's corporate value over the medium to long term.

Going forward, if any matters concerning the agreements that require disclosure arise, the Group will promptly issue announcements.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>